Emerging experimental drugs such as RIP3 (29), P2X7 receptor antagonists (30), GSK-3β inhibitors (31) and an Nrf2 agonist (32) inhibited the development of LN in MRL/lpr mice by modulating he NLRP3/ASC/caspase-1 inflammasome activity, which highlights the importance and criticality of the NLRP3/ASC/caspase-1 inflammasome in LN. Here, NLRP3 is linked to lobular neoplasia.